Technical Analysis for NTLA - Intellia Therapeutics, Inc.

Grade Last Price % Change Price Change
D 130.49 -0.97% -1.28
NTLA closed down 0.97 percent on Friday, October 15, 2021, on 75 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: Nov 3
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Up
Historical NTLA trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Multiple of Ten Bullish Other -0.97%
Wide Bands Range Expansion -0.97%
Wide Bands Range Expansion 4.10%
Stochastic Reached Oversold Weakness 1.88%
Multiple of Ten Bearish Other 1.88%
Wide Bands Range Expansion 1.88%
Oversold Stochastic Weakness 1.88%
New Downtrend Bearish 3.62%
Jack-in-the-Box Bearish Bearish Swing Setup 3.62%
Older End-of-Day Signals for NTLA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Intellia Therapeutics, Inc. Description

Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. It has a strategic collaboration and license agreement with Novartis focused on the development of new ex vivo CRISPR/Cas9-based therapies. Intellia Therapeutics Inc. was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics Inc. in July 2014. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biology Immune System Emerging Technologies Genetics Molecular Biology Hepatitis B Precision Medicine Metabolism Amyloid Liver Disease Hematopoietic Stem Cell Hepatitis B Virus Amyloidosis Chimeric Antigen Receptor Chimeric Antigen Receptor T Cell Liver Diseases Antitrypsin Deficiency Cell Product CRISPR Genome Editing Inborn Errors Of Metabolism Transthyretin Cas9 Transthyretin Amyloidosis

Is NTLA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 202.73
52 Week Low 22.17
Average Volume 873,081
200-Day Moving Average 100.82
50-Day Moving Average 149.52
20-Day Moving Average 136.28
10-Day Moving Average 128.33
Average True Range 8.53
ADX 26.16
+DI 16.42
-DI 25.56
Chandelier Exit (Long, 3 ATRs) 133.26
Chandelier Exit (Short, 3 ATRs) 143.58
Upper Bollinger Bands 155.69
Lower Bollinger Band 116.88
Percent B (%b) 0.35
BandWidth 28.48
MACD Line -6.46
MACD Signal Line -6.39
MACD Histogram -0.073
Fundamentals Value
Market Cap 7.71 Billion
Num Shares 59.1 Million
EPS -2.00
Price-to-Earnings (P/E) Ratio -65.11
Price-to-Sales 36.49
Price-to-Book 7.69
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 138.77
Resistance 3 (R3) 139.53 137.52 137.39
Resistance 2 (R2) 137.52 135.41 137.15 136.93
Resistance 1 (R1) 134.01 134.11 133.01 133.25 136.47
Pivot Point 132.00 132.00 131.50 131.63 132.00
Support 1 (S1) 128.49 129.89 127.49 127.73 124.51
Support 2 (S2) 126.48 128.59 126.11 124.05
Support 3 (S3) 122.97 126.48 123.59
Support 4 (S4) 122.21